Boston Scientific (BSX)
(Real Time Quote from BATS)
$86.62 USD
-0.97 (-1.11%)
Updated Nov 15, 2024 03:05 PM ET
3-Hold of 5 3
C Value B Growth C Momentum C VGM
Boston Scientific (BSX) Price Targets
| Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
|---|---|---|---|
| $98.00 | $110.00 | $86.00 | 11.88% |
Find the top stocks with the greatest target price potential and Zacks Rank of 1 or 2
Price Target
Based on short-term price targets offered by 29 analysts, the average price target for Boston Scientific comes to $98.00. The forecasts range from a low of $86.00 to a high of $110.00. The average price target represents an increase of 11.88% from the last closing price of $87.59.
Analyst Price Targets (29)
Broker Rating
Boston Scientific currently has an average brokerage recommendation (ABR) of 1.29 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 28 brokerage firms. The current ABR compares to an ABR of 1.29 a month ago based on 28 recommendations.
Of the 28 recommendations deriving the current ABR, 23 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 82.14% and 7.14% of all recommendations. A month ago, Strong Buy made up 82.14%, while Buy represented 7.14%.
Broker Rating Breakdown
Brokerage Recommendations
| Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|---|
| Strong Buy | 23 | 23 | 23 | 23 | 23 |
| Buy | 2 | 2 | 2 | 3 | 3 |
| Hold | 3 | 3 | 3 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| ABR | 1.29 | 1.29 | 1.29 | 1.25 | 1.25 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
| Date | Brokerage Firm | Analyst | Previous | Current |
|---|---|---|---|---|
| 10/24/2024 | Goldman Sachs | David H Roman | Strong Buy | Strong Buy |
| 10/24/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
| 10/24/2024 | Not Identified | Not Identified | Hold | Hold |
| 10/24/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
| 10/24/2024 | Raymond James | Jayson T Bedford | Strong Buy | Strong Buy |
| 10/24/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
| 10/24/2024 | Canaccord Genuity | William J Plovanic | Strong Buy | Strong Buy |
| 10/24/2024 | Wells Fargo Securities | Lawrence H Biegelsen | Strong Buy | Strong Buy |
| 10/24/2024 | Mizuho SecuritiesUSA | Anthony Petrone | Strong Buy | Strong Buy |
| 10/23/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
| 10/23/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
| 10/23/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
| 10/21/2024 | Cowen & Co. | Joshua T Jennings | Strong Buy | Strong Buy |
| 10/18/2024 | Needham & Company | Michael Matson | Moderate Buy | Hold |
| 10/14/2024 | BTIG | Marie Thibault | Strong Buy | Strong Buy |
| 10/14/2024 | Truist Securities | Richard Newitter | Strong Buy | Strong Buy |
| 10/1/2024 | Evercore Partners | Vijay Kumar | Strong Buy | Strong Buy |
| 8/22/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
| 8/5/2024 | Piper Sandler | Matthew O'Brien | Strong Buy | Strong Buy |
| 7/30/2024 | Daiwa America | Narumi Nakagiri | Not Available | Strong Buy |
| 7/26/2024 | UBS | Danielle Antalffy | Strong Buy | Strong Buy |
| 7/25/2024 | Robert W. Baird & Co. | David Rescott | Strong Buy | Strong Buy |
| 4/3/2024 | Argus Research Corp. | John M Eade | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
| Current ABR | 1.29 |
| ABR (Last week) | 1.29 |
| # of Recs in ABR | 28 |
| Average Target Price | $98.00 |
| LT Growth Rate | 13.80% |
| Industry | Medical - Products |
| Industry Rank by ABR | 82 of 252 |
| Current Quarter EPS Est: | 0.65 |
BSX FAQs
Boston Scientific Corporation (BSX) currently has an average brokerage recommendation (ABR) of 1.29 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 28 brokerage firms.
The average price target for Boston Scientific Corporation (BSX) is $98.00. The current on short-term price targets is based on 12 reports.
The forecasts for Boston Scientific Corporation (BSX) range from a low of $86 to a high of $110. The average price target represents a increase of $11.88 from the last closing price of $87.59.
The current UPSIDE for Boston Scientific Corporation (BSX) is 11.88%
Based on short-term price targets offered by 29 analysts, the average price target for Boston Scientific comes to $98.00. The forecasts range from a low of $86.00 to a high of $110.00. The average price target represents an increase of 11.88% from the last closing price of $87.59.